Skip to main content
. 2020 Apr 21;41(7):986–994. doi: 10.1038/s41401-020-0400-z

Fig. 3. Schematic illustration of shedding prodrug vesicles for cancer immunotherapy.

Fig. 3

a The preparation procedure for enzyme-activatable prodrug vesicles (EAPV) designed to codeliver PEGylated PS and an IDO-1 inhibitor (NLG919); b The mechanisms by which EAPVs enhance antitumor efficacy via synergic triggering of ICD and combating IDO-1-mediated adaptive immune resistance; c Immunofluorescence image of CRT expressed on the surface of tumor cells in the CT26 tumor xenograft model (scale bar = 50 μm); d Immunofluorescence image of HMGB1 release from tumor cells in the CT26 tumor xenograft model (scale bar = 25 μm); e The ratio of mature DCs in tumor-draining lymph nodes; f The number of intratumor infiltrating T lymphocytes in tumor tissue; g Kyn to Trp molar ratio determined for the CT26 tumor tissue; and h Tumor growth curves of the CT26 xenograft tumors. Adapted with permission from [86]. Copyright (2019) American Chemical Society.